This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
by Zacks Equity Research
Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.
ABSIPositive Net Change LQDAPositive Net Change IMCRPositive Net Change KVUEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use
by Zacks Equity Research
GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.
GILDNegative Net Change MRKPositive Net Change LQDAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC
by Zacks Equity Research
Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.
GILDNegative Net Change MRKPositive Net Change LQDAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
by Zacks Equity Research
Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosis program, clarifying a potential path toward full approval.
GALTPositive Net Change LQDAPositive Net Change IMCRPositive Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Biotech's Silent Resurgence (5-Year Base Breakout)
by Andrew Rocco
The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.
NVSPositive Net Change PFENegative Net Change LLYPositive Net Change IBBPositive Net Change
biotechnology biotechs
Regeneron's Applications for gMG Drug Accepted by FDA and EMA
by Zacks Equity Research
Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially unique dosing schedule.
REGNNegative Net Change SNYPositive Net Change ALNYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
by Zacks Equity Research
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
RHHBYPositive Net Change MRKPositive Net Change EXELPositive Net Change NTRAPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push
by Zacks Equity Research
Novo Nordisk stock rises 6% after the launch of a EUR 60.2M foundation-backed initiative to speed cardiometabolic drug discovery and support Europe-wide innovation.
NVOPositive Net Change LQDAPositive Net Change IMCRPositive Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
by Zacks Equity Research
DFTX stock surges 50% as phase III data show its single-dose, investigational MDD therapy delivers rapid, durable symptom improvements and meets all key goals.
LQDAPositive Net Change IMCRPositive Net Change INDVNegative Net Change DFTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bull of the Day: Liquidia Corporation (LQDA)
by Ethan Feller
Liquidia Corporation shares have been rallying as the company turns net profitable amid successful drug commercialization.
LQDAPositive Net Change
biotechnology biotechs